Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Chief Financial Officer | September 02, 2026 | September 03, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Principal Accounting Officer | August 03, 2020 | August 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,277 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 1,733 · Balance 117,277 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
bluebird bio, Inc.
Report date August 03, 2020 · Filed August 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,512 |
Reported balance
After 2020-08-03 transaction · row 1
1 source rowRow 1 · 2020-08-03 · Sale · Disposed 82 · Balance 9,512 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 18, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 21:15 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,733 | $7.14 | $12,380.38 |
DisclosureSEC source: 0001725663-26-000007 · wk-form4_1788470155.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,277 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:39 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,500 | $12.95 | $32,375.00 |
DisclosureSEC source: 0001725663-26-000005 · wk-form4_1775162353.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,010 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 11,388 | $13.02 | $148,215.96 |
DisclosureSEC source: 0001725663-26-000003 · wk-form4_1773261246.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,510 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 5,089 | $13.00 | $66,162.60 |
DisclosureSEC source: 0001725663-26-000003 · wk-form4_1773261246.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,898 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 7,988 | $12.25 | $97,892.14 |
DisclosureSEC source: 0001725663-26-000002 · wk-form4_1772833002.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,987 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 23:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 5,712 | $11.76 | $67,152.56 |
DisclosureSEC source: 0001725663-26-000001 · wk-form4_1772580032.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,975 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 2,939 | $11.66 | $34,262.57 |
DisclosureSEC source: 0001725663-26-000001 · wk-form4_1772580032.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,687 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 66,600 | $0.00 Strike: $11.93 | $0.00 |
DisclosureSEC source: 0001725663-26-000001 · wk-form4_1772580032.xml · derivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,600 Underlying: Common Stock · 66,600 shares Expires 2036-03-01 F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 44,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001725663-26-000001 · wk-form4_1772580032.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,626 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 21:30 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 8,910 | $9.98 | $88,931.60 |
DisclosureSEC source: 0001725663-25-000004 · wk-form4_1764019838.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,026 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,734 | $5.43 | $9,415.97 |
DisclosureSEC source: 0001725663-25-000003 · wk-form4_1757019718.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,936 F1 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,134 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-25-000019 · wk-form4_1743798826.xml · derivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,023 Underlying: Common Stock · 11,134 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option fully vested on November 16, 2024. Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 11,134 | $2.10 | $23,381.40 |
DisclosureSEC source: 0001689375-25-000019 · wk-form4_1743798826.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,784 | $10.67 | $19,035.28 |
DisclosureSEC source: 0001689375-25-000016 · wk-form4_1742416340.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,536 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:00 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 4,929 | $11.68 | $57,563.82 |
DisclosureSEC source: 0001689375-25-000014 · wk-form4_1741125633.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,320 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 63,300 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001689375-25-000014 · wk-form4_1741125633.xml · derivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,300 Underlying: Common Stock · 63,300 shares Expires 2035-03-01 F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:00 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 42,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-25-000014 · wk-form4_1741125633.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,249 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-24-000068 · wk-form4_1733264776.xml · derivative · entry 6 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,157 Underlying: Common Stock · 5,000 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F4 · derivative.exercise_date: The shares subject to this option fully vested on November 16, 2024. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 5,000 | $20.00 | $99,978.00 |
DisclosureSEC source: 0001689375-24-000068 · wk-form4_1733264776.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,849 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 22:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 5,000 | $2.10 | $10,500.00 |
DisclosureSEC source: 0001689375-24-000068 · wk-form4_1733264776.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-24-000068 · wk-form4_1733264776.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,157 Underlying: Common Stock · 1,000 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F4 · derivative.exercise_date: The shares subject to this option fully vested on November 16, 2024. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $19.97 | $19,970.30 |
DisclosureSEC source: 0001689375-24-000068 · wk-form4_1733264776.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,849 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 1,000 | $2.10 | $2,100.00 |
DisclosureSEC source: 0001689375-24-000068 · wk-form4_1733264776.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-24-000065 · wk-form4_1731534419.xml · derivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,157 Underlying: Common Stock · 6,000 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 8,637 | $19.98 | $172,562.08 |
DisclosureSEC source: 0001689375-24-000065 · wk-form4_1731534419.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,849 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 6,000 | $2.10 | $12,600.00 |
DisclosureSEC source: 0001689375-24-000065 · wk-form4_1731534419.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,195 | $14.97 | $47,832.35 |
DisclosureSEC source: 0001689375-24-000055 · wk-form4_1726000485.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,486 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.52 to $15.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 165 | $15.13 | $2,495.79 |
DisclosureSEC source: 0001689375-24-000049 · wk-form4_1725576389.xml · nonDerivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,681 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 941 | $15.42 | $14,513.42 |
DisclosureSEC source: 0001689375-24-000049 · wk-form4_1725576389.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,846 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 14 | $17.70 | $247.83 |
DisclosureSEC source: 0001689375-24-000049 · wk-form4_1725576389.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,787 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 149 | $16.93 | $2,521.90 |
DisclosureSEC source: 0001689375-24-000049 · wk-form4_1725576389.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,801 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 462 | $15.76 | $7,281.63 |
DisclosureSEC source: 0001689375-24-000049 · wk-form4_1725576389.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,950 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,758 | $14.95 | $26,282.10 |
DisclosureSEC source: 0001689375-24-000039 · wk-form4_1720643672.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,412 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-24-000017 · wk-form4_1710880362.xml · derivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,157 Underlying: Common Stock · 9,000 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 9,000 | $2.10 | $18,900.00 |
DisclosureSEC source: 0001689375-24-000017 · wk-form4_1710880362.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,086 | $12.31 | $50,285.18 |
DisclosureSEC source: 0001689375-24-000008 · wk-form4_1709933772.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,170 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.05 to $12.515, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 00:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,471 | $12.28 | $18,062.11 |
DisclosureSEC source: 0001689375-24-000005 · wk-form4_1709686024.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,256 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 405 | $13.37 | $5,413.76 |
DisclosureSEC source: 0001689375-24-000005 · wk-form4_1709686024.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,727 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 339 | $12.42 | $4,211.40 |
DisclosureSEC source: 0001689375-24-000005 · wk-form4_1709686024.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,132 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 46,800 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001689375-24-000005 · wk-form4_1709686024.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,800 Underlying: Common Stock · 46,800 shares Expires 2034-03-01 F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2028. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:47 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 30,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-24-000005 · wk-form4_1709686024.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,471 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 94 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · derivative · entry 10 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,157 Underlying: Common Stock · 94 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 94 | $16.67 | $1,566.98 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 7 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| December 26, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 94 | $2.10 | $197.40 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 6 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,206 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · derivative · entry 9 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,251 Underlying: Common Stock · 10,206 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,677 | $16.48 | $60,610.56 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.06 to $16.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 6,529 | $15.24 | $99,513.06 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,248 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.95 to $15.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 10,206 | $2.10 | $21,432.60 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · derivative · entry 8 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,457 Underlying: Common Stock · 2,200 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,200 | $15.07 | $33,154.66 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.95 to $15.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.